Skandinaviska Enskilda Banken AB publ Acquires Shares of 61,744 Sanofi (NASDAQ:SNY)

Key Points

• Skandinaviska Enskilda Banken AB has acquired a new position in Sanofi, purchasing 61,744 shares valued at approximately $3,424,000 during the first quarter.
• Analysts have set a consensus price target of $62.00 for Sanofi, with various ratings including "buy" and "strong buy" from multiple investment firms.
• Sanofi's stock recently traded at $49.35, with a 12-month price range between $45.80 and $60.12, and a market capitalization of $121.03 billion.

Skandinaviska Enskilda Banken AB publ purchased a new stake in Sanofi (NASDAQ:SNY - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 61,744 shares of the company's stock, valued at approximately $3,424,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Invesco Ltd. lifted its position in shares of Sanofi by 3.5% during the 4th quarter. Invesco Ltd. now owns 12,059,283 shares of the company's stock worth $581,619,000 after purchasing an additional 408,752 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Sanofi by 3.8% during the 4th quarter. Bank of America Corp DE now owns 12,017,140 shares of the company's stock worth $579,587,000 after purchasing an additional 441,637 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Sanofi by 88.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock worth $522,991,000 after purchasing an additional 5,091,304 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Sanofi by 10.8% during the 4th quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company's stock worth $182,164,000 after purchasing an additional 369,530 shares during the last quarter. Finally, Nuveen Asset Management LLC lifted its position in shares of Sanofi by 1.0% during the 4th quarter. Nuveen Asset Management LLC now owns 3,676,224 shares of the company's stock worth $177,304,000 after purchasing an additional 34,660 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Sanofi Stock Performance

NASDAQ SNY traded up $0.73 during trading on Friday, reaching $46.37. The company's stock had a trading volume of 1,216,599 shares, compared to its average volume of 2,561,767. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37. The firm has a market cap of $113.72 billion, a price-to-earnings ratio of 16.57, a P/E/G ratio of 1.12 and a beta of 0.48. Sanofi has a twelve month low of $44.73 and a twelve month high of $60.12. The business's fifty day moving average price is $49.21 and its 200-day moving average price is $52.09.

Wall Street Analyst Weigh In

Several brokerages recently commented on SNY. Guggenheim reiterated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Barclays reiterated an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. Morgan Stanley set a $56.00 price target on shares of Sanofi in a research note on Monday, June 2nd. Finally, BNP Paribas began coverage on shares of Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target on the stock. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Sanofi has a consensus rating of "Buy" and a consensus price target of $62.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.